Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q2 FY23 Earnings Presentation
23 slides from Viyash Scientific's earnings presentation, Nov 7, 2022
Slide 1: SeQuent Announces Q2 FY23 Results
SeQuent Announces Q2 FY23 Results Revenues at ₹ 3,376 Million, Emerging Markets and India drive formulations growth Company to acquire 100% stake in Tineta Pharma Private Limited Mumbai, November 07, 2022 SeQuent Scientific Limited (SeQuent) which has businesses across Animal Health (Alivira) & Anal
Slide 2: Press release continued: Tineta acquisition and earnings call
Our Formulations business grew by 14.8% on constant currency basis, driven by a strong performance in Emerging Markets and India. We continue to accelerate our efforts in these markets while simultaneously implementing profitability improvement initiatives in our businesses in Europe & Turkey. SeQue
Slide 3: Forward-looking statements and investor contacts
orientcapital ISIN: INE807F01027 I REUTERS: EQU.BO A division of Link Intime India Pvt Ltd Nachiket Kale Website: www.sequent.in nachiket.kale@linkintime.co.in | +91 9920940808 Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking stat
Slide 4: Earnings Presentation Q2 FY23
Earnings Presentation Q2 FY23 7th November 2022 1
Slide 5: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 6: Management Commentary
Management Commentary Q2 FY23 has been challenging owing to macro environment headwinds, even though we continue to see strong performance in select markets. While the overall business grew 2.9% in constant currency terms, the reported revenue declined by 3.7% over Q2 FY22. EBITDA before ESOP costs
Slide 7: Q2 FY23: Challenging quarter in a tough macro environment
Q2 FY23 : Challenging quarter in a tough macro environment Macro-environment Short-Term Industry Headwinds Challenges Geo-political uncertainty Subdued demand Currency volatilities EU Antibiotic regulations Inflation High energy & Input costs Business Response Reprioritize markets & segments Product
Slide 8: Performance Overview
& ° ‘quent itty MY 23 oS Eg £0 Y fa EEEITIT! HEIETIIT! HEETIII HBHEELTLII! HHEELII I HBHEHEEtTEItTI I HHEHERESTS HHEHEsEtds tI HHeeEosESsE is | i ee ee ee ee ee |
Slide 9: Revenue performance by Geography
Revenue performance by Geography All values in ₹ Mn QoQ Gr% YoY Gr% YoY Gr% Revenue Distribution Q2 FY23 Q1 FY22 QoQ Gr% Q2 FY22 YoY Gr% H1 FY23 H1 FY22 YoY Gr% (in CC) (In cc) (In cc) Formulations 2,395 2,448 (2.2%) 1.1% 2,365 1.3% 14.8% 4,842 4,632 4.5% 17.1% Europe 899 1,036 (13.3%) (11.2%) 1,055
Slide 10: Formulations: Sustaining momentum in key markets
Formulations : Sustaining momentum in key markets Key Updates Q2 revenues at ₹ 2.39 Bn, +14.8% (cc) in markets despite stiff macro environment FDFs 1000+ H1 revenues at ₹ 4.84 Bn; +11% 3-year CAGR anchored by a globally diversified business model Strong performance in focus growth areas: Emerg
Slide 11: Diversified formulations to continue driving sustainable value creation
Diversified formulations to continue driving sustainable value creation India Emerging Markets Europe Market Presence LATAM - Swine & Poultry Cattle, Swine, Poultry, ^Companion, Species Coverage Cattle & Poultry Turkey - Cattle & Ruminant ^Equine – Multi species model Other EMs - Multi spe
Slide 12: API: Challenging quarter… Acceleration program in place
API : Challenging quarter… Acceleration program in place Key Updates Commercial Q2 revenues at ₹ 920 Mn, performance impacted by erratic demand and price pressures 33 APIs H1 revenues at ₹ 1.81 Bn, 3-year CAGR flat, new product pipeline to drive near-term growth Business contribution from regu
Slide 13: API business quality improving: Regulated markets, top customers and new products
API business quality Improving : Regulated markets, Top customers and new products Key Growth Drivers Long-term partnerships & CDMO Contribution of Regulated markets ~ 65% (3 projects underway) Deepen Customer engagement (New customer organization Contribution of Top-10 customers ~ 55% implemented)
Slide 14: Improving quality of API business
Improving quality of API business: Regulated markets & Top animal health customers contribution continuously increasing 61% 60% 67% 68% Sustainable Growth Model 28% 30% 43% 45% Regulated markets penetration increasing - predictable & stable 15% 13% 12% 8% Contribution of Top-10 animal health players
Slide 15: New Business Acquisition in India
New Business Acquisition in India
Slide 16: Acquisition of Tineta Pharma: Top livestock company in India
Acquisition of Tineta Pharma: Top livestock company in India Tineta Pharma Pvt. Ltd. • 25 year old profitable company in India • FY 2021-22 Revenues exceeded ₹ 810 Mn • Top Animal Health player focused on livestock sector • Strong on ground commercial presence with robust field force of 270+ • Estab
Slide 17: Sequent strengthens position as Top-10 Veterinary player in India
Sequent strengthens position as Top-10 Veterinary player in India Top-10 Vitum Performance Animal Health company in Pioneer in udder management - Commercial engine to drive India, key player in livestock Premium brand, preferred choice upswing in formulations run-rate Synergies+ ~ ₹1,900 Mn 50+ Bran
Slide 18: Financials
oven Ability In Life Sciences J Seauent Financials
Slide 19: Consolidated Financials
Consolidated Financials All values in ₹ Mn Q2 FY23 Q1 FY23 Q2 FY22 H1 FY23 H1 FY22 FY22 Particulars Unaudited Unaudited Unaudited Unaudited Unaudited Audited Revenue from Operations 3,376 3,413 3,506 6,789 6,711 14,128 Material Consumption (1,979) (1,967) (2,004) (3,946) (3,667) (7,930) Gross Margin
Slide 20: Q2 Operating Performance – One offs
Q2 Operating Performance – One offs All values in ₹ Mn Particulars Q2 FY23 Q1 FY23 EBITDA (Pre ESOP) 150 201 % of Revenue 4.4% 5.9% One offs Plant safety and improvement 32 - Hyperinflation impact 24 17 Adjusted EBITDA (pre ESOP) 205 218 % of Revenue 6.1% 6.4% 17
Slide 21: Key Balance Sheet Items
Key Balance Sheet Items All values in ₹ Mn Particulars Sep- 22* Mar-22^ Balance Sheet Highlights Shareholders Funds 7,375 6,921 Rise in Net Debt on account of additional working capital facility in Minority Interest 443 480 Net Debt 3,405 2,542 India and Turkey – ₹ 396 Mn Investments 1 368 Capex
Slide 22: For details, feel free to contact
For details, feel free to contact: Krunal Shah Abhishek Singhal Nachiket Kale Company Secretary Investor Relations Consultant Investor Relations Advisor +91 22 4111 4779 abhishek.s@sequent.in +91 9920940808 investorrelations@sequent.in nachiket.kale@linkintime.co.in Registered Office: 301/A, ‘Dosti
Slide 23: Thank You
oven Ability In Life Sciences J Seauent Thank You